Peter Chambré

Since joining as a Senior Adviser in September 2007, Peter Chambré has in a short time shown his leadership abilities to create new business opportunities with 3i, becoming Chairman of two portfolio companies: 

• Nurtured by 3i from its days as a spin-out, ApaTech is a pioneer in bone graft technology and poised to become a world-leading orthobiologics company.  Peter’s track record of growing international healthcare businesses made him the ideal person to guide ApaTech through the next crucial phase of its evolution.
• Peter was also appointed Non-executive Chairman of Alpharma API, a worldwide developer and supplier of specialist active pharmaceutical ingredients in the growing antibiotics markets, following the 3i-supported buyout from NYSE-listed Alpharma Inc. in a deal valued at around €250m.

Peter was previously CEO of Cambridge Antibody Technology Group plc, a world leader in the discovery and development of human antibody therapeutics.  Under his leadership, the listed company successfully transitioned into a profitable product development business, ultimately being acquired by AstraZeneca for around €900m in 2006.

In Peter’s view, 3i is a particularly attractive partner for healthcare businesses: “Because of the strong underlying growth and the opportunities for high returns, healthcare is a fundamentally attractive sector.  To unlock its potential, you have to bring together the right combination of science, people and capital.  3i is uniquely placed to do that because of its breadth of view.”

Peter’s interest in working with 3i stems from the exciting opportunities that arise from its unique deal flow: “3i identifies companies that are at points of change and helps them to evolve rapidly.  That dovetails perfectly with my personal goals.  As a Senior Adviser at 3i, I have the opportunity to tap into the very broad pipeline of deals that 3i’s commitment to the sector and investment strength offers, as well as to generate transactions myself.  This gives me an exceptionally wide range of companies to evaluate.”

“My ambition is to continue to lead healthcare companies through their next phase of successful development and thereby create exceptional returns – I believe that those are goals that can best be met in partnership with 3i.”